Capital Performance Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Capital Performance Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,664	Closed	-$220K	–	322
2025 Q1	$220K	Buy	+1,664	New	+$207K	0.05%	225
2024 Q4	–	Sell	-1,012	Closed	-$74K	–	2845
2024 Q3	$74K	Buy	+1,012	New	+$76.1K	0.02%	255

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Capital Performance Advisors's ITCI Position: Q2 2025 in Review

Capital Performance Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,664 shares — an estimated $220K sold.

Capital Performance Advisors first reported a position in ITCI in Q3 2024 and held it in 2 quarters. The position peaked at $220K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Capital Performance Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Capital Performance Advisors sold 1,664 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $220K.
Capital Performance Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 2 quarters.
Capital Performance Advisors's Intra-Cellular Therapies Inc. position peaked at $220K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Capital Performance Advisors's 13F filing for Q2 2025, filed 4 Aug 2025.